GlycoVaxyn signs license agreement and enters into R&D collaboration with JPI

GlycoVaxyn AG, which is engaged in the development of vaccines, has signed a license agreement and entered into three-year R&D collaboration with Janssen Pharmaceuticals, Inc., or JPI, to develop a multi-valent bacterial vaccine employing GlycoVaxyn's bio-conjugation technology.

"Bacterial pathogens that exist in multiple pathogenic strains pose significant challenges for developing vaccines that target these strains," said Michael Wacker, co-founder and chief scientific officer of GlycoVaxyn. "Our recombinant DNA-based vaccine technology is particularly well-suited for polyvalent conjugate vaccines and should make the development and commercialization of these vaccines more feasible and reliable."

GlycoVaxyn will collaborate with JPI's affiliate, Crucell Holland BV, on the development of the multi-valent vaccine until proof-of-concept, after which JPI will be responsible for later-stage clinical studies and world-wide commercialization. The consideration to GlycoVaxyn includes an upfront payment, milestone payments, royalties as well as reimbursement of R&D expenses.

Philippe Dro, CEO of GlycoVaxyn added, "This collaboration is a further confirmation of the position GlycoVaxyn is about to occupy in the vaccine development space. The whole team is dedicated to establish GlycoVaxyn's technology as a powerful platform able to generate innovative vaccine candidates. We are very pleased to work together with JPI and Crucell and to be able to contribute to their vaccine development ambitions."